AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body. T cells, a primary type of white blood cell or lymphocyte, circulate in the blood and monitor for virally infected or cancerous cells. Among these, T cells that infiltrate solid tumors are known as tumor-infiltrating lymphocytes, or TILs. However, not all TILs effectively recognize and attack tumor cells. To address this, scientists have now employed artificial intelligence (AI) to create a predictive model that can identify the most effective TILs for use in cancer immunotherapy.

The new AI-driven predictive model, called TRTpred developed by scientists at Ludwig Cancer Research (New York, NY, USA) ranks T cell receptors (TCRs) according to their tumor reactivity. To create TRTpred, the researchers utilized 235 TCRs from patients with metastatic melanoma, already categorized as tumor-reactive or non-reactive. They input the global gene-expression profiles of the T cells harboring each TCR into a machine learning model to identify patterns distinguishing tumor-reactive T cells from their inactive counterparts. This model, enhanced with additional algorithms, supports personalized cancer treatments tailored to the unique cellular composition of each patient’s tumors.

The TRTpred model was used to analyze TILs from 42 patients with melanoma, gastrointestinal, lung, and breast cancer, pinpointing tumor-reactive TCRs with about 90% accuracy. The selection process was further refined using a secondary algorithmic filter to isolate those T cells with “high avidity”—meaning they bind strongly to tumor antigens. It was observed that T cells identified by TRTpred and this secondary filter as both tumor-reactive and high avidity were predominantly located within the tumors rather than in the surrounding stromal tissue. This aligns with previous studies suggesting that effective T cells often deeply penetrate tumor islets.

A third filter was then introduced to enhance the identification of TCRs recognizing a diverse array of tumor antigens. This filter groups TCRs based on similar physical and chemical characteristics, assuming TCRs in each group recognize the same antigen. This enhanced system, named MixTRTpred, was then tested by growing human tumors in mice, extracting TCRs from their TILs, and employing MixTRTpred to identify T cells that were tumor-reactive, had high avidity, and targeted multiple tumor antigens. The researchers then engineered mouse T cells to express these TCRs and demonstrated that these modified cells could effectively eradicate tumors when reintroduced into the mice.

“The implementation of artificial intelligence in cellular therapy is new and may be a game-changer, offering new clinical options to patients,” said Ludwig Lausanne’s Alexandre Harari, who led the study published on May 7, 2024 in Nature Biotechnology.

Related Links:
Ludwig Cancer Research

Visit expo >

Gold Member

Turnkey Packaging Solution

HLX

Gold Member

C-Reactive Protein Reagent

CRP Ultra Wide Range Reagent Kit

New

Leptin ELISA

Leptin AccuBind ELISA Kit

New

Herpes Virus Test

Human Herpes Virus (HHV-6) Real Time PCR Kit